ITP0811
ITP0811
ITP0811
from
$541.00
Price in reward points: 541
- Catalog: ITP0811
- Gene/Protein: WWOX
- Product Description: Immunotag™ WWOX (phospho Tyr33) Polyclonal Antibody
-
Description
-
Specifications
Antibody Specification Datasheet 
IMPORTANT NOTE This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. Target Protein WWOX (Tyr33) Clonality Polyclonal Storage/Stability -20°C/1 year Application WB,IHC-p,ELISA Recommended Dilution Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/10000. Not yet tested in other applications. Concentration 1 mg/ml Reactive Species Human,Mouse Host Species Rabbit Immunogen The antiserum was produced against synthesized peptide derived from human WWOX around the phosphorylation site of Tyr33. AA range:18-67 Specificity Phospho-WWOX (Y33) Polyclonal Antibody detects endogenous levels of WWOX protein only when phosphorylated at Y33. Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen Form Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. Gene Name WWOX Accession No. Q96KM3 Alternate Names WWOX; FOR; WOX1; WW domain-containing oxidoreductase; Fragile site FRA16D oxidoreductase Description disease:Defects in WWOX may be involved in esophageal squamous cell carcinoma (ESCC) [MIM:133239].,disease:Defects in WWOX may be involved in several cancer types. The gene spans the second most common chromosomal fragile site (FRA16D) which is frequently altered in cancers. Alteration of the expression and expression of some isoforms is associated with cancers. However, it is still unclear if alteration of WWOX is directly implicated in cancerogenesis or if it corresponds to a secondary effect.,domain:The WW 1 domain mediates interaction with TP53, and probably TP73, TFAP2C, LITAF and WBP1.,function:Probable oxidoreductase, which acts as a tumor suppressor and plays a role in apoptosis. May function synergistically with TP53/p53 to control genotoxic stress-induced cell death. May also play a role in tumor necrosis factor (TNF)-mediated cell death.,PTM:Phosphorylated upon genotoxic stress. Phosphorylation of Tyr-33 regulates interaction with TP53, TP73 and MAPK8. May also regulate proapoptotic activity.,similarity:Belongs to the short-chain dehydrogenases/reductases (SDR) family.,similarity:Contains 2 WW domains.,subcellular location:Partially localizes to the mitochondria. Translocates to the nucleus upon genotoxic stress or TNF stimulation (By similarity). Isoform 5 and isoform 6 may localize in the nucleus.,subunit:Interacts with TP53, TP73/p73 and MAPK8. Interacts with MAPT/TAU (By similarity). Forms a ternary complex with TP53 and MDM2. Interacts with ERBB4, LITAF and WBP1. May interact with COTE1/C1orf2 and SCOTIN.,tissue specificity:Widely expressed. Strongly expressed in testis, prostate, and ovary. Overexpressed in cancer cell lines. Isoform 5 and isoform 6 may only be expressed in tumor cell lines., Protein Function disease:Defects in WWOX may be involved in esophageal squamous cell carcinoma (ESCC) [MIM:133239].,disease:Defects in WWOX may be involved in several cancer types. The gene spans the second most common chromosomal fragile site (FRA16D) which is frequently altered in cancers. Alteration of the expression and expression of some isoforms is associated with cancers. However, it is still unclear if alteration of WWOX is directly implicated in cancerogenesis or if it corresponds to a secondary effect.,domain:The WW 1 domain mediates interaction with TP53, and probably TP73, TFAP2C, LITAF and WBP1.,function:Probable oxidoreductase, which acts as a tumor suppressor and plays a role in apoptosis. May function synergistically with TP53/p53 to control genotoxic stress-induced cell death. May also play a role in tumor necrosis factor (TNF)-mediated cell death.,PTM:Phosphorylated upon genotoxic stress. Phosphorylation of Tyr-33 regulates interaction with TP53, TP73 and MAPK8. May also regulate proapoptotic activity.,similarity:Belongs to the short-chain dehydrogenases/reductases (SDR) family.,similarity:Contains 2 WW domains.,subcellular location:Partially localizes to the mitochondria. Translocates to the nucleus upon genotoxic stress or TNF stimulation (By similarity). Isoform 5 and isoform 6 may localize in the nucleus.,subunit:Interacts with TP53, TP73/p73 and MAPK8. Interacts with MAPT/TAU (By similarity). Forms a ternary complex with TP53 and MDM2. Interacts with ERBB4, LITAF and WBP1. May interact with COTE1/C1orf2 and SCOTIN.,tissue specificity:Widely expressed. Strongly expressed in testis, prostate, and ovary. Overexpressed in cancer cell lines. Isoform 5 and isoform 6 may only be expressed in tumor cell lines., Usage For Research Use Only! Not for diagnostic or therapeutic procedures. - Reviews
| Antibody Specification | |
| Datasheet | |
| IMPORTANT NOTE | This product is custom manufactured with a lead time of 3-4 weeks. Once in production, this item cannot be cancelled from an order and is not eligible for return. |
| Target Protein | WWOX (Tyr33) |
| Clonality | Polyclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,IHC-p,ELISA |
| Recommended Dilution | Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/10000. Not yet tested in other applications. |
| Concentration | 1 mg/ml |
| Reactive Species | Human,Mouse |
| Host Species | Rabbit |
| Immunogen | The antiserum was produced against synthesized peptide derived from human WWOX around the phosphorylation site of Tyr33. AA range:18-67 |
| Specificity | Phospho-WWOX (Y33) Polyclonal Antibody detects endogenous levels of WWOX protein only when phosphorylated at Y33. |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen |
| Form | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Gene Name | WWOX |
| Accession No. | Q96KM3 |
| Alternate Names | WWOX; FOR; WOX1; WW domain-containing oxidoreductase; Fragile site FRA16D oxidoreductase |
| Description | disease:Defects in WWOX may be involved in esophageal squamous cell carcinoma (ESCC) [MIM:133239].,disease:Defects in WWOX may be involved in several cancer types. The gene spans the second most common chromosomal fragile site (FRA16D) which is frequently altered in cancers. Alteration of the expression and expression of some isoforms is associated with cancers. However, it is still unclear if alteration of WWOX is directly implicated in cancerogenesis or if it corresponds to a secondary effect.,domain:The WW 1 domain mediates interaction with TP53, and probably TP73, TFAP2C, LITAF and WBP1.,function:Probable oxidoreductase, which acts as a tumor suppressor and plays a role in apoptosis. May function synergistically with TP53/p53 to control genotoxic stress-induced cell death. May also play a role in tumor necrosis factor (TNF)-mediated cell death.,PTM:Phosphorylated upon genotoxic stress. Phosphorylation of Tyr-33 regulates interaction with TP53, TP73 and MAPK8. May also regulate proapoptotic activity.,similarity:Belongs to the short-chain dehydrogenases/reductases (SDR) family.,similarity:Contains 2 WW domains.,subcellular location:Partially localizes to the mitochondria. Translocates to the nucleus upon genotoxic stress or TNF stimulation (By similarity). Isoform 5 and isoform 6 may localize in the nucleus.,subunit:Interacts with TP53, TP73/p73 and MAPK8. Interacts with MAPT/TAU (By similarity). Forms a ternary complex with TP53 and MDM2. Interacts with ERBB4, LITAF and WBP1. May interact with COTE1/C1orf2 and SCOTIN.,tissue specificity:Widely expressed. Strongly expressed in testis, prostate, and ovary. Overexpressed in cancer cell lines. Isoform 5 and isoform 6 may only be expressed in tumor cell lines., |
| Protein Function | disease:Defects in WWOX may be involved in esophageal squamous cell carcinoma (ESCC) [MIM:133239].,disease:Defects in WWOX may be involved in several cancer types. The gene spans the second most common chromosomal fragile site (FRA16D) which is frequently altered in cancers. Alteration of the expression and expression of some isoforms is associated with cancers. However, it is still unclear if alteration of WWOX is directly implicated in cancerogenesis or if it corresponds to a secondary effect.,domain:The WW 1 domain mediates interaction with TP53, and probably TP73, TFAP2C, LITAF and WBP1.,function:Probable oxidoreductase, which acts as a tumor suppressor and plays a role in apoptosis. May function synergistically with TP53/p53 to control genotoxic stress-induced cell death. May also play a role in tumor necrosis factor (TNF)-mediated cell death.,PTM:Phosphorylated upon genotoxic stress. Phosphorylation of Tyr-33 regulates interaction with TP53, TP73 and MAPK8. May also regulate proapoptotic activity.,similarity:Belongs to the short-chain dehydrogenases/reductases (SDR) family.,similarity:Contains 2 WW domains.,subcellular location:Partially localizes to the mitochondria. Translocates to the nucleus upon genotoxic stress or TNF stimulation (By similarity). Isoform 5 and isoform 6 may localize in the nucleus.,subunit:Interacts with TP53, TP73/p73 and MAPK8. Interacts with MAPT/TAU (By similarity). Forms a ternary complex with TP53 and MDM2. Interacts with ERBB4, LITAF and WBP1. May interact with COTE1/C1orf2 and SCOTIN.,tissue specificity:Widely expressed. Strongly expressed in testis, prostate, and ovary. Overexpressed in cancer cell lines. Isoform 5 and isoform 6 may only be expressed in tumor cell lines., |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |